Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Telavancin is primarily excreted as unchanged drug in the urine. Lopinavir/ritonavir is metabolised by CYP3A4. Lopinavir/ritonavir is unlikely to affect telavancin elimination. Telavancin is unlikely to inhibit or induce CYP3A4. However, caution should be exercised as both drugs have possible risks of QT prolongation and/or TdP on the CredibleMeds.org website. If coadministration is necessary, clinical monitoring including ECG assessment is recommended.